EmGenisys has published a peer-reviewed paper in the Journal of IVF-Worldwide demonstrating that its EzGrader product can assess bovine embryos with accuracy comparable to expert embryologists. The study found the AI achieved 81.7% agreement with experts on embryo stage classification and 95.2% accuracy on determining whether embryos were transferable, addressing long-standing subjectivity in embryo evaluation. The research will be showcased at the Association of Embryo Technologies conference in Ireland this September, where the company will also launch its European subsidiary.
“The moat that we’re building through peer-reviewed science and global recognition will help us scale faster and give veterinarians confidence in adopting our technology,” CEO and co-founder Cara Wells told bizblip. The findings show that EzGrader allows novice embryologists to perform at the level of practitioners with 20 or more years of experience, reducing training time and making embryo transfer more accessible. This could lower costs for livestock producers while improving breeding outcomes.
Cara Wells, EmGenisys CEO
Founded in 2019 in Houston, Texas, EmGenisys develops AI-driven tools to support livestock producers. Its cloud-based platform processes embryo videos captured via smartphone microscopes, giving farmers and veterinarians rapid insights into embryo health. The company operates with a small hybrid team of full-time and part-time staff and is expanding its technology into human IVF through its Viable Biosciences subsidiary.
To date, EmGenisys has raised $1.6 million in grants and competitions, including a $250,000 prize from Bio Tools Innovator, and recently closed a $1.5 million seed round led by Grit Road Partners. The company has also applied for a €2.5 million European Innovation Council grant to support its global rollout.
Links:
